Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015. Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059-4. doi: 10.1016/…

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J…

(...) Prof. Dr. Christoph Sarrazin: „Wir mussten schmerzhaft lernen, dass es einen Point of no Return gibt. Ab diesem Zeitpunkt in der Erkrankung kann man zwar mit den DAA das Virus aus dem Körper eliminieren, aber es gelingt nicht mehr…

The International Network on Hepatitis in Substance Users (INHSU) is an international organization dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs…

Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct Acting Antivirals. Prenner S, et al. J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053-3. doi: 10.1016/j.jhep.2017.01.020. [Epub ahead of print] Abstr…

Jason Grebely,Tracy Swan, Matthew Hickman, Julie Bruneau, Philip Bruggmann, Olav Dalgard, Alain Litwin, Markus Backmund, Gregory J. Dore, on behalf of the International Network for Hepatitis in Substance Users Journal of Hepatology, Volume 0, Issue…